This study developed polymeric nanoparticles (NPs) conjugated with monoclonal antibody (mAb) for glioblastoma treatment. In this study, the physicochemical properties of poly (butyl cyanoacrylate) (PBCA) NPs were characterized. The cytotoxicity of NPs conjugated with mAb (NPs + mAb) and in vitro drug release evaluation was tested on glioblastoma cell lines. Their therapeutic efficiency and side effects were then assessed in vivo in a rat model of glioblastoma. The conjugation of NPs to mAb revealed an average particle size of 365 nm and conjugation efficiency of 41.95%. The findings also showed that cytotoxicity was augmented by 40% compared to the free form of carboplatin. Moreover, in vivo studies showed that body weight remained relatively stable in rats treated by NPs + mAb and their survival time was longer (23.5 days) compared to rats treated with free carboplatin (19.5 days). In addition, ex vivo investigation showed that rats administered with NPs + mAb exhibited less side effects in the brain, kidney and liver compared to other groups.
Read full abstract